In this issue:
- Plasma and breast milk pharmacokinetics of tenofovir alafenamide
- HCV virologic response at 4 weeks with glecaprevir/pibrentasvir
- Global change in HCV prevalence between 2015 and 2020
- Liver injury after SARS-CoV-2 vaccination
- Glecaprevir/pibrentasvir for HCV in patients aged ≥75 years
- Four weeks of treatment with glecaprevir/pibrentasvir
- HCV-related depression, anxiety, and neurocognitive performance
- Mortality in people with chronic HBV infection
- Point-of-care HCV testing at community pharmacies
Please login below to download this issue (PDF)